Recommendations issued to prevent VTE in maternal patients

December 11, 2013
Recommendations issued to prevent VTE in maternal patients

(HealthDay)—The Physician-Patient Alliance for Health & Safety, the Institute for Healthcare Improvement, and the National Perinatal Association have developed safety recommendations aimed at preventing venous thromboembolism (VTE) in maternal patients.

A panel of experts, brought together by the Patient-Physician Alliance for Health & Safety, developed VTE safety recommendations for prevention of VTE.

The safety recommendations include four steps: (1) patients should be evaluated for VTE risk using an easy-to-use automated scoring system; (2) depending on whether the mother is antepartum or postpartum, the recommended prophylaxis regimen should be provided; (3) the patient should be reassessed every 24 hours or upon occurrence of a significant event such as surgery; and (4) upon hospital discharge, the mother should be provided with appropriate VTE prevention education.

"The risks of VTE are four to five times higher for pregnant than for non-pregnant women," MaryAnne Laffin, N.P., immediate past president of the National Perinatal Association, said in a statement. "For the safety of pregnant women, the National Perinatal Association therefore encourages all hospitals to adopt these VTE safety recommendations."

Explore further: Study finds high clot risk for women admitted to hospital during pregnancy

More information: More Information

Related Stories

Post-op prophylactic heparin poses very low bleed risk

November 11, 2013

(HealthDay)—The risk of hemorrhage seems to be very low when prophylactic low-molecular-weight heparin (LMWH) is initiated 24 to 36 hours after degenerative spine surgery but the associated venous thromboembolism (VTE) ...

VTE occurs in 13 percent of head, neck cancer surgery cases

October 4, 2013

(HealthDay)—Venous thromboembolism (VTE) rates in a prospective cohort of head and neck cancer surgical patients are higher than previously reported in retrospective studies, according to research published online Sept. ...

VTE risk varies by hormone therapy formulation

September 18, 2012

(HealthDay)—The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral estrogen-progestin ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.